Biocon Ltd. shares rose over 2% following the U.S. launch of YESINTEK™ (ustekinumab-kfce) by its subsidiary, Biocon Biologics Ltd. (BBL). As one of the first biosimilars to Stelara® (ustekinumab), YESINTEK offers a cost-effective alternative for treating chronic autoimmune diseases like Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis.
Patients will have access to YESINTEK in all formulations available for the reference biologic, including prefilled syringes and vials in multiple strengths. The biosimilar has secured commercial payor coverage at launch and features a robust patient assistance program, with eligible patients potentially paying as little as $0.
YESINTEK, a monoclonal antibody, inhibits IL-12 and IL-23 signaling, which are key factors in immune-mediated diseases. Clinical studies confirm its equivalence to Stelara® in terms of safety, efficacy, pharmacokinetics, and immunogenicity. The U.S. Food and Drug Administration (FDA) approved YESINTEK in December 2024, further validating its reliability.
Biocon shares opened at ₹324.05, reaching a high of ₹328.65 and a low of ₹321.15 during the trading session. The stock’s 52-week range spans from ₹244.55 to ₹404.70, reflecting market volatility.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
